STOCK TITAN

Kindred Biosciences to Present at Guggenheim Animal Health Summit

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary

Kindred Biosciences (NASDAQ: KIN) is set to present at the Guggenheim Animal Health Summit on December 7, 2020, at 10am ET. CEO Dr. Richard Chin will join the panel discussing how biologics will transform veterinary practices. Additionally, he will hold one-on-one meetings with investors to discuss recent developments and key therapeutic programs. Kindred Biosciences focuses on developing biologics that improve pets' lives, leveraging validated human medicine targets for safe and effective treatments.

Positive
  • None.
Negative
  • None.

SAN FRANCISCO, Dec. 2, 2020 /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced that Dr. Richard Chin, Chief Executive Officer, will present on the "How Biologics Will Change Veterinary Practices" panel at the Guggenheim Animal Health Summit at 10am ET on Monday, December 7, 2020.

Dr. Chin will also be available for one-on-one meetings. During this time, investors will have the opportunity to discuss recent developments, study results from key therapeutic programs in development, and upcoming milestones.

About Kindred Biosciences 

Kindred Biosciences is a biopharmaceutical company developing innovative biologics focused on saving and improving the lives of pets. Its mission is to bring to pets the same kinds of safe and effective medicines that human family members enjoy. The Company's strategy is to identify targets that have already demonstrated safety and efficacy in humans and to develop therapeutics based on these validated targets for dogs and cats. KindredBio has a deep pipeline of novel biologics in development across many therapeutic classes, alongside state-of-the-art biologics manufacturing capabilities and a broad intellectual property portfolio.

For more information, visit: www.kindredbio.com

Contact
Katja Buhrer 
katja.buhrer@kindredbio.com 
(917) 969-3438

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/kindred-biosciences-to-present-at-guggenheim-animal-health-summit-301185094.html

SOURCE Kindred Biosciences, Inc.

FAQ

What is Kindred Biosciences presenting at the Guggenheim Animal Health Summit?

Kindred Biosciences will present on how biologics will change veterinary practices on December 7, 2020.

Who will present at the Guggenheim Animal Health Summit for KIN?

CEO Dr. Richard Chin will represent Kindred Biosciences at the summit.

When is the Guggenheim Animal Health Summit presentation by KIN?

The presentation is scheduled for 10am ET on December 7, 2020.

What opportunities will be available during the KIN presentation?

Investors can engage in one-on-one meetings to discuss developments and therapeutic programs.

What focus does Kindred Biosciences have in its biopharmaceutical development?

Kindred Biosciences focuses on developing biologics for pets based on validated human medicine targets.

KIN

NASDAQ:KIN

KIN Rankings

KIN Latest News

KIN Stock Data

Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
Burlingame